Sunday, June 12, 2016

Lupin - Avoid

Company Background :
Lupin Limited is an India-based transnational pharmaceutical company. The Company is engaged in the producing, developing and marketing of branded and generic formulations, and active pharmaceutical ingredients (APIs).

The Company's brands include Gluconorm, Tonact, Rablet, Budamate, Telekast, Rcinex, Clopitab, Telista, Ramistar and Akt. The Company manufactures products in the therapy areas, such as anti-TB, cardiovascular, anti-asthma, diabetology, central nervous system, gynecology, gastro-intestinal (GI), anti-infective and others.

The Company's subsidiaries include Lupin Pharmaceuticals Inc., Kyowa Pharmaceutical Industry Co., Ltd., Pharma Dynamics (Proprietary) Ltd., Hormosan Pharma GmbH, Multicare Pharmaceuticals Philippines, Inc., Generic Health Pty Ltd., Kyowa CritiCare Co., Ltd., Lupin Holdings B.V., Lupin Atlantis Holdings SA and Lupin Pharma Canada Ltd., among others.

Stock Performance:

During the last 1 year the scrip has given following returns

1 year  -27%
6 months -26%
3 months -28%
1 week -6%

Recommendation :

Avoid till clarity emerges on USFDA front


Smart Investor -
Equity Research

No.24 Pattamal Plaza
3rd Cross Kammanahalli
Whatsapp -09880080321

Smart Investor
BSE, NSE SharesTips